Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of lenalidomide and dexamethasone for chronic lymphocytic leukaemia that has got worse or come back after treatment (LenD)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at low dose lenalidomide and the steroid dexamethasone for people who had already had treatment for chronic lymphocytic leukaemia (CLL).
More about this trial
- see how well the combination of dexamethasone and low dose lenalidomide works for people in this situation
- learn more about the side effects
Summary of results
- 4 people (33%) stopped treatment early because they had serious side effects
- 4 people (33%) stopped treatment early because their CLL got worse
- got a bit better in 3 people (25%)
- stayed the same in 2 people (17%)
- got worse in 7 people (58%)
How to join a clinical trial
Dr Amit C. Nathwani
NIHR Clinical Research Network: Cancer
University College London (UCL)